H syndrome mimicking Erdheim Chester disease: new entity and therapeutic perspectives

Not available.

[1]  A. Yoshizawa,et al.  Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis , 2022, Blood advances.

[2]  Jason R. Young,et al.  International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults , 2022, Blood.

[3]  Jason R. Young,et al.  Classical and non‐classical phenotypes of Erdheim–Chester disease: Correlating clinical, radiographic and genotypic findings , 2021, British journal of haematology.

[4]  Chengjie Deng,et al.  Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. , 2021, Clinical immunology.

[5]  P. Westenend,et al.  Long term follow up of mTOR inhibition for Erdheim-Chester disease. , 2020, Blood.

[6]  C. McElroy,et al.  Adult stem cell deficits drive Slc29a3 disorders in mice , 2019, Nature Communications.

[7]  S. Guthery,et al.  H syndrome: 5 new cases from the United States with novel features and responses to therapy , 2017, Pediatric Rheumatology.

[8]  A. Fischer,et al.  Revised Classification of Histiocytoses and Neoplasms of the Macrophage-dendritic Cell Lineages Histiocyte and Dendritic Cell Lineages the " L " (langerhans) Group , 2022 .

[9]  S. Ferretti,et al.  Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. , 2015, Blood.

[10]  Brian Y. Hwang,et al.  Epidural spinal involvement of Erdheim–Chester disease causing myelopathy , 2015, Journal of Clinical Neuroscience.

[11]  O. Abdel-Wahab,et al.  Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. , 2014, Blood.

[12]  Stephen A Baldwin,et al.  The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. , 2013, Molecular aspects of medicine.

[13]  D. Seshasayee,et al.  Equilibrative Nucleoside Transporter 3 Deficiency Perturbs Lysosome Function and Macrophage Homeostasis , 2012, Science.

[14]  P. Devilee,et al.  Mutations in SLC29A3, Encoding an Equilibrative Nucleoside Transporter ENT3, Cause a Familial Histiocytosis Syndrome (Faisalabad Histiocytosis) and Familial Rosai-Dorfman Disease , 2010, PLoS genetics.

[15]  Y. Ramot,et al.  H syndrome: the first 79 patients. , 2014, Journal of the American Academy of Dermatology.